GSK plc 6-K, filed Oct 17, 2022
GSK plc (GSK)
6-K
2022-10-17
For: 2022-10-17
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on October 17, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 17 October 2022, London UK
US FDA approves Menveo in a new single-vial presentation to help
prevent disease caused by meningococcal bacteria serogroups A, C,
Y, and W
●
Single-vial presentation option removes the need
for reconstitution of Menveo before use in individuals 10 through 55
years of age.
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug
Administration (FDA) has approved a new presentation
of
Menveo [Meningococcal (Groups A,
C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate
Vaccine] for individuals aged 10 to 55 years to
help prevent
invasive meningococcal disease caused by Neisseria
meningitidis serogroups A, C, Y, and W.
The Menveo one-vial
presentation now comes in a ready to use single
vial giving
healthcare providers a more convenient option.
The Menveo one-vial
presentation will initially be available to US federal customers,
with broader availability anticipated in
mid-2023.
Invasive meningococcal disease (IMD), known as meningitis, is an
uncommon but serious illness that can cause life-threatening
complications or even death.1 IMD
is caused by Neisseria
meningitidis, with the majority
of cases caused by serogroups (A, B, C, W, Y) in most of the
world.1 Among
those who contract meningitis, one in ten will die, despite
treatment, sometimes in as little as 24 hours.1 One
in five (up to 20%) of meningitis survivors suffer long-term
consequences, such as brain damage, amputations, hearing loss and
nervous system problems.1
Roger Connor, President, Vaccines and Global Health, GSK,
said:
"Outbreaks of this dangerous disease continue to occur, impacting
families, health systems and society. This
FDA approval of Menveo one-vial
presentation offers greater convenience to healthcare providers to
help prevent this disease in at-risk populations in the United
States."
The original two-vial presentation of Menveo requiring reconstitution, was approved by
the FDA in 2010 and remains available for use in individuals from
two months to 55 years of age.
About Menveo
The Menveo vaccine (supplied
in a two-vial presentation) for meningococcal groups A, C, Y, and
W has
been approved in over 60 countries, with more than 72 million doses
distributed worldwide since 2010. It offers extensive evidence of
immunogenicity and a well-characterised safety
profile. Menveo does
not prevent Neisseria meningitidis serogroup
B infections.
The US Prescribing Information is available here.
Important Safety Information
for Menveo in the US
The following is based on the US Prescribing Information
for Menveo. Please consult the full Prescribing Information
for all the labeled safety information.
|
●
|
Do not
administer Menveo to individuals with a
severe allergic reaction (e.g., anaphylaxis) to a previous dose
of Menveo, to any
component of this vaccine, or to any other diphtheria
toxoid-containing vaccine.
|
|
●
|
Appropriate
medical treatment must be available should an acute allergic
reaction, including an anaphylactic reaction, occur following
administration of Menveo.
|
|
●
|
Syncope
(fainting) has occurred in association with administration
of Menveo. Procedures
should be in place to avoid injury from fainting.
|
|
●
|
Some
individuals with altered immunocompetence, including some
individuals receiving immunosuppressant therapy, may have reduced
immune responses to Menveo.
|
|
●
|
Persons
with certain complement deficiencies and persons receiving
treatment that inhibits terminal complement activation (for
example, eculizumab) are at increased risk for invasive disease
caused by N.
meningitidis, including invasive disease caused by
serogroups A, C, Y, and W, even if they develop antibodies
following vaccination with Menveo.
|
|
●
|
Guillain-Barré
syndrome (GBS) has been reported in temporal relationship following
administration of another US-licensed meningococcal quadrivalent
polysaccharide conjugate vaccine. The decision to
administer Menveo to individuals with a
history of GBS should take into account the expected benefits and
potential risks.
|
|
●
|
Apnea
following intramuscular vaccination has been observed in some
infants born prematurely. A decision about when to
administer Menveo to an infant born
prematurely should be based on consideration of the individual
infant's medical status and the potential benefits and possible
risks of vaccination.
|
|
●
|
Common
solicited adverse reactions among children initiating vaccination:
at 2 months of age and receiving the 4-dose series were tenderness
and erythema at injection site, irritability, sleepiness,
persistent crying, change in eating habits, vomiting, and diarrhea;
at 7 months through 23 months of age and receiving the 2-dose
series were tenderness and erythema at injection site,
irritability, sleepiness, persistent crying, change in eating
habits, and diarrhea; at 2 through 10 years of age who
received Menveo were injection site pain,
erythema, irritability, induration, sleepiness, malaise, and
headache. Common solicited adverse reactions among adolescents and
adults aged 11 through 55 years who received a single dose
of Menveo were
pain at the injection site, headache, myalgia, malaise, and nausea.
Across all age groups, some events were severe. Similar rates of
solicited adverse reactions among adolescents and adults were
observed following a single booster dose.
|
|
●
|
In two
clinical studies, there were no notable differences in frequency
and severity of solicited adverse reactions in individuals who
received Menveo one-vial presentation
compared to individuals who received the 2-vial
presentation.
|
|
●
|
Vaccination
with Menveo may
not result in protection in all vaccine recipients.
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Alison
Hunt
|
+1 540
742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
References
[1] Centers for Disease
Control and Prevention. Vaccine Information Statements. Available
at: Meningococcal
Vaccine Information Statement | CDC. Accessed
October 2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
17, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|